Russia’s sovereign wealth fund, the RDIF (Russian Direct Investment Fund) has announced initial safety results of the world’s first study on using a combination of AstraZeneca and Sputnik V vaccines. The first component of Sputnik V i.e. Sputnik Light was used.
For the study, fifty volunteers were vaccinated and new individuals have been invited to participate in the trail. It continued saying, “Interim analysis of the data demonstrates a high safety profile for the combined use of the vaccines with no serious adverse side events or cases of coronavirus after vaccination.”
In the month of August, the fund along with its partners will release initial data on the immunogenicity of the mixed use of AstraZeneca’s COVID-19 vaccine and Sputnik V’s first component in Azerbaijan.
Furthermore, the CEO of RDIF, Kirill Dmitriev has said that based on the high efficacy of the heterogeneous boosting i.e. vaccine cocktail approach, RDIF was first in the world to initiate partnerships with other markers of COVID-19 vaccines. He pointed out that the fund’s clinical trial with AstraZeneca was the first partnership of such kind.
Clinical trials of vaccine cocktails are being conducted in multiple countries including the United Arab Emirates (UAE), where the volunteers are being vaccinated.